重组人生长激素治疗青春期前特发性矮小儿童

Effect of recombinant human growth hormone therapy in prepubertal children with idiopathic short stature

目的:观察重组人生长激素(rhGH)治疗青春期前特发性矮小的疗效。方法:24例特发性矮小病儿分为2组,治疗组女孩10例,男孩2例,起始治疗年龄为(10.1±s1.9)a,予rhGH0.10～0.13U·kg-1·d-1,治疗时间(0.8±0.3)a。对照组女孩10例,男孩2例,起始观察年龄(9.9±1.7)a,未予rhGH治疗,观察时间(1.1±0.5)a。结果:治疗组治疗后生长的速率为(8.7±1.9)cm·a-1,对照组为(5.0±0.7)cm·a-1,2组差异有非常显著意义(P<0.01)。治疗组对骨龄的身高标准差值(HtSDSBA)增加0.4±0.4,预测成人身高(PHt)增加了(3.1±0.9)cm;对照组HtSDSBA减少0.3±0.5,PHt降低(0.9±1.7)cm,2组比较差异均有非常显著意义(P<0.01)。结论:rhGH对青春期前特发性矮小儿童的生长有促进作用,能改善其PHt。

AIM: To observe the effect of recombinant human growth hormone (rhGH) in treating pre pubertal children with idiopathic short stature (ISS). METHODS: Twenty-four ISS children were divided into two groups. Twelve children in trea ting group (M 2, F 10; initial age of treatment (10.1±(s1.9))a ) undertak en with rh GH 0.10-0.13 (U·kg^(-1)·)d^(-1) for an average treating time of (0.8 ±0. 3) were comp ared with 12 children (M 2, F 10; initial age of observation (9.9±1.7)a ) of th e control group without given rhGH with the average observing time of ((1.1)±0. 5)a. RESULTS: After treatment, the growth velocity (GV) was (8.7±1.9) cm·a^(-1) in treati ng group and (5.0±0.7) cm·a^(-1) in control group. The height standard dev iation score of bone age (HtSDS_(BA)) increased 0.4±0.4 and predicted adult height (PHt) increased (3.1±0.9)cm in treating group. The HtSDS_(BA) decreas ed 0.3±0.5 and PHt decreased (0.9±1.7) cm in control group. There were signifi c ant difference between the two groups (P<(0.01)). CONCLUSION: The rhGH can stimulate the growth of prepubertal children with ISS simultaneous ly increase with PHt.